Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Given To Launch Next-Gen Colonoscopy PillCam In Europe In November

This article was originally published in The Gray Sheet

Executive Summary

Given Imaging expects its PillCam COLON 2 endoscopy capsule will overcome many of the limitations identified in a recent clinical trial comparing its first-generation PillCam COLON to standard colonoscopy

You may also be interested in...

Covidien Ventures Into Capsule-Based Endoscopy With Given Imaging Acquisition

The $860 million purchase agreement will give Covidien the dominant capsule endoscopy platform on the market as the company hopes for FDA approval this year of PillCam COLON 2 as a less invasive alternative for patients who are unable to undergo a colonoscopy.

Reimbursement Briefs: PillCam Reimbursement In Japan; 3-D Mammo Code Withdrawn; CMS Data Sharing

Japan will reimburse PillCam COLON. 3-D mammography CPT code application withdrawn from AMA CPT Editorial Panel meeting. CMS unveils new virtual research data-sharing tool.

Given Imaging’s PillCam Colon 2 Strategy Shift Will Delay Screening Claim

Firm initially will pursue diagnostic imaging claim for its PillCam Colon 2 video capsule, rather than a screening claim, as the fastest route to U.S. market. The strategy shift follows preliminary clinical trial data review.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts